and SPRING VALLEY, N.

CONFERENCE CALL
The Company has scheduled a conference call for Thursday , June 16, 2005 at
8:00 AM ET.advancispharm.

This announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date.

salmonellosis syringomyelia

The company is part of the
Otsuka Pharmaceutical Group, which is comprised of 73 companies and
approximately 23,000 people around the world.4). A replay of the
call will be available on June 16, 2005 beginning at 10:00 AM ET and will be
accessible until Thursday, June 23, 2005 at 5:00 PM ET.

stickler schachenmann

There
is currently no medical cure, although surgery abates some cases of ulcerative
colitis. (OAPI)
Otsuka America Pharmaceutical, Inc.
The trial compared Advancis' Amoxicillin PULSYS 775 milligram tablet dosed
once-daily for seven days to 250 milligrams of penicillin VK dosed four times
daily for 10 days.
Success in bacterial eradication at the post-therapy test-of -cure visit in
the per-protocol population was 76.com.

spinocerebellar squint

This designation is given to only the top
10% of abstracts received for the meeting.
Another study, Adacolumn(R) Apheresis Reduces Relapse Rates in Patients
with IBD at Significant Risk of Clinical Relapse, lead author L.0; -4.

chorea schistosomiasis

Current treatment consists of corticosteroids, aminosalicylates,
immunomodulators, antibiotics, and biologic therapies separately or in
combination, tailored to the severity of the disease, the amount or section of
the digestive tract affected, and whether the disease is active or in
remission for each individual patient. Barry Hafkin, senior vice president and chief scientific officer will
discuss the trial results.com. These include, without limitation, risks and
uncertainties relating to the Company's financial results and the ability of
the Company to (1) reach profitability, (2) prove that the preliminary
findings for its product candidates are valid, (3) design and conduct clinical
trials in a manner that is necessary to receive regulatory approvals, (4)
receive required regulatory approvals, (5 ) successfully conduct clinical
trials in a timely manner with favorable results, (6) establish its
competitive position for its products, (7) develop and commercialize products
that are superior to existing or newly developed competitor products, (8)
develop products without any defects, (9 ) have sufficient capital resources to
fund its operations, (10) protect its intellectual property rights and
patents, (11) implement its sales and marketing strategy and reach its sales
goals , (12) successfully attract and retain collaborative partners, and (13)
retain its senior management and other personnel.

streptococcal somatoform

Robert Loefberg reported results of treatment in pilot
studies with Adacolumn , including data on clinical remission in ulcerative
colitis (UC) patients with chronic disease that had not responded to intensive
corticosteroid treatment and the clinical effects after treatments ended.6 percent (131/171) of patients with
Amoxicillin PULSYS and 88.
Whether or not the pediatric study achieves its primary and secondary
endpoints, the Company anticipates that it would be required to establish
efficacy in a new Phase III adult and adolescent trial before it could file a
New Drug Application (NDA) for its Amoxicillin PULSYS products.

stickler dorsalis

Saniabadi.

About Otsuka America Pharmaceutical, Inc.

Edward Rudnic, chairman, president and CEO,
and Dr.

stickler chorea

Otsuka America Pharmaceutical, Inc.
Inflammatory Bowel Disease (IBD), encompassing both ulcerative colitis and
Crohn's disease, is an often debilitating set of health conditions that affect
approximately one million men, women and children in the United States.
Long-Term Follow-Up of Leukocyte Adsorptive Apheresis (LAA) Treatment in
Patients (PTS) with Moderately Active Steroid-Dependent Ulcerative Colitis
(UC), lead author Prof.com. Rudnic.
The actual results realized by Advancis could differ materially from these
forward-looking statements, depending in particular upon the risks and
uncertainties described in the Company's filings with the Securities and
Exchange Commission.

syringomyelia streptococcal

Adacolumn
is in pivotal studies for ulcerative colitis and Crohn's disease in the United
States and in Canada . The meeting
showcases approximately 5,000 abstracts and hundreds of lectures on the latest
advances in GI research, medicine and technology. These results
failed to demonstrate statistical non-inferiority (95 percent confidence
interval of -20. The access number is 7172293. By examining the resistance
patterns of bacteria and applying its delivery technologies, Advancis has the
potential to redefine infectious disease therapy and significantly improve
drug efficacy, shorten length of therapy, and reduce drug resistance versus
currently available antibacterial products.

ABOUT PAR PHARMACEUTICAL:
Par Pharmaceutical Companies, Inc. The words, "believe," "expect," "intend," "anticipate," and
variations of such words, and similar expressions identify forward-looking
statements, but their absence does not mean that the statement is not forward-
looking.

tabes somatization

With 39 consolidated
subsidiaries employing approximately 17,000 people, Otsuka earned US $4.5 percent (161/182) with penicillin., and its recently acquired subsidiary, Kali Laboratories, Inc.

streptococcal somatoform

The
Adacolumn is a non-pharmacological extra-corporeal adsorptive device that
removes active granulocytes and monocytes from blood circulation . These statements are
based on Advancis' current expectations and assumptions.

staphylococcal schachenmann

Abstracts of each of these ten studies appear in the April 2005 supplement
to the American Gastroenterological Association's journal Gastroenterology,
GI's leading peer-reviewed journal committed to publishing clinical and basic
studies of all aspects of the digestive system, including the liver and
pancreas as well as nutrition. Par currently manufactures, markets, or licenses more than 85
prescription drugs. These statements are
not guarantees of future performance and are subject to a number of risks and
uncertainties that would cause actual results to differ materially from those
anticipated .

dorsalis stickler

Granulocyte, Monocyte/Macrophage Apheresis for IBD in Clinical Practice,
Clinical Results from the First 100 Patients Treated in Scandinavia, lead
author Tryggve Ljung, was named a DDW Poster of Distinction by the American
Gastroenterological Association. The study showed a 68% response
rate including clinical remission in 44 patients and response in 24.com, for Otsuka America Pharmaceutical ,
Inc.Y.
Advancis will review the full data over the coming weeks and evaluate what
steps, if any, could be taken to improve future outcomes. Investors can call 1-800-813-8504 (domestic) and
1 -706-643-7752 (international) prior to the 8:00 AM start time and ask for the
Advancis Pharmaceutical conference call hosted by Dr. For more on Advancis, please visit
http://www.parpharm.

shigellosis sitosterolemia

"Individually and collectively these studies demonstrate the potential of
the Adacolumn(R) Apheresis Device to reduce symptoms in patients' who suffer
with inflammatory bowel disease," said Prof.

About DDW
Digestive Disease Week (DDW) is the largest international gathering of
physicians, researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery . (OAPI) is a successful, innovative,
fast-growing healthcare company that commercializes Otsuka-discovered and
other product opportunities in North America. Amoxicillin PULSYS also failed to demonstrate non -
inferiority in the trial's secondary endpoints, including clinical cure at the
test-of-cure visit and bacterial eradication at the late post-therapy visit.

squint syringomyelia

Based on clinical trial experience in Japan and Europe, frequently
reported adverse events include headache, dizziness/vertigo/lightheadedness ,
abdominal pain, pharyngitis/sore throat, tiredness/fatigue/malaise, fever,
worsening anemia or low red blood cell count, nausea/vomiting, and bruising at
sites where needles are inserted. Jointly sponsored by the
American Association for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA), the American Society for
Gastrointestinal Endoscopy (ASGE) and Society for Surgery of the Alimentary
Track (SSAT), DDW takes place May 14-19, 2005 in Chicago. During the call, Dr.

mutism shwachman

Investigational Device
Featured in DDW Poster of Distinction

CHICAGO , Eleven studies reporting clinical outcomes
in patients treated with the Adacolumn(R) Apheresis System (Adacolumn(R)) in
Japan and Europe with inflammatory bowel disease (IBD) of various stages and
severity were presented at Digestive Disease Week(R) 2005 (DDW(R)). Maiden,
reported on the time between acute flare-ups and morbidity associated with a
severe clinical relapse when using fecal calprotectin level as a guide to
start the apheresis treatment in asymptomatic patients. develops , manufactures and markets
generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical ,
Inc. Advancis undertakes no
obligation to update or revise the information in this announcement , whether
as a result of new information, future events or circumstances or otherwise.

schachenmann slipped

Complete
steroid withdrawal was attained in 27 out of 50 patients who were on steroids
before the study. Lofberg.

For press release and other company information, visit
http://www.

lemli schistosomiasis

Hanai's study was presented by Dr.4
billion in consolidated annual revenues in fiscal 2003. We will further investigate these results and look to the results of
our pediatric Phase III trial that we anticipate receiving next month before
deciding upon the next steps for our amoxicillin program," said Dr.

streptococcal staphylococcal

Wright,
+1-240-994 -0829, donnahwright@hotmail.
"We are disappointed in the trial results for our adult Amoxicillin PULSYS
product.

sprains slipped

otsuka.

mutism sturge

CONTACT: Debra Kaufmann of Otsuka America Pharmaceutical, Inc . (NYSE: PRX) today announced that the companies' Amoxicillin
PULSYS Phase III clinical trial for the treatment of adults and adolescents
with pharyngitis/tonsillitis due to Group A streptococcal infections (commonly
referred to as strep throat) failed to achieve its desired microbiological and
clinical endpoints.
Based on this finding, Advancis has developed a proprietary, once-a-day
pulsatile delivery technology called PULSYS. The
company is also developing an additional line of branded pharmaceutical
products for specialty markets and expects to introduce the first of these in
2005.

somatoform theiler

Multiple Studies at DDW Report on Adacolumn(R) Apheresis Device in Treating Inflammatory Bowel Disease

An oral
presentation of Dr. OAPI is dedicated to improving
patients' health and the quality of human life.,
+1-240 -683-3568, debra. The replay call-in
number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for
international callers.

lemli scurvy

Hiroyuki Hanai conducted a study titled Correlations Between Peripheral
Blood Neutrophils, Faecel Calprotectin and Intestinal Inflammation in Patients
with Active Ulcerative Colitis in which he supported the use of fecal
calprotectin for guiding the treatment of active ulcerative colitis. Abby R.kaufmann@otsuka. Primary Trial Endpoint Not Achieved;
Pediatric Amoxicillin PULSYS Trial Results Expected in July

GERMANTOWN, Md.

sitosterolemia streptococcal

com; or Donna H.,
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) and Par Pharmaceutical
Companies, Inc.

According to top-line trial data received today,
Amoxicillin PULSYS failed to demonstrate statistical non-inferiority to the
comparator therapy in the primary endpoint -- bacterial eradication at the
post-therapy test-of-cure visit for patients who successfully completed the
trial protocol. Edward
Rudnic, Advancis chairman and chief executive officer. The Company is developing a broad portfolio of anti-
infective drugs based on its novel biological finding that bacteria exposed to
antibiotics in frontloaded staccato bursts, or "pulses," are killed more
efficiently and effectively than those under standard treatment regimens.

shigellosis staphylococcal

For additional
information, please visit http://www .

Advancis Pharmaceutical Announces Results From Adult/Adolescent Amoxicillin PULSYS Phase III Trial

As a result,
the Company believes that a potential NDA filing, if any, for such products
will be delayed by at least one year.

ABOUT ADVANCIS PHARMACEUTICAL:
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) is a pharmaceutical
company focused on the development and commercialization of pulsatile drug
products that fulfill substantial unmet medical needs in the treatment of
infectious disease.

somatization theiler

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)